Navigation Links
MimiVax Appoints Jerry Jacobs Jr. to Board of Directors; SurVaxM Immunotherapy Partnership Opportunities at BIO International June 19-22, 2017.
Date:6/12/2017

MimiVax, LLC, a cancer immunotherapy company today announced that Jerry Jacobs, Jr, co-CEO of Delaware North has joined its Board of Directors. Mr. Jacobs brings deep entrepreneurial insights and business resources to the company.

Mr. Jacobs is co-CEO of Delaware North, one of the most admired family-owned and operated companies in the world. Delaware North is headquartered in Buffalo, New York and has annual revenues of $3 billion, employing more than 55,000 employees on four continents. The University at Buffalo medical school was recently named the Jacobs School of Medicine and Biomedical Sciences, in recognition of the Mr. Jacobs family’s steadfast support.

MimiVax’s lead immunotherapeutic agent, SurVaxM, is currently in a Phase II multicenter clinical trial, and a recently completed interim data analysis puts the program in great position for continued advancement. MimiVax is looking forward to Mr. Jacobs’ strategic guidance for the company and helping it progress much needed new therapies for brain cancer patients.

MimiVax executives will be discussing partnering opportunities for its lead program SurVaxM, as well as pre-clinical pipeline assets: novel anti-survivin monoclonal antibody and CAR-T based approaches for solid tumors at the annual BIO International Conference, taking place between June 19-22, 2017 at the San Diego Convention Center.

Michael Ciesielski, PhD, Chief Scientific Officer; and Anil Goyal, PhD, VP Business Development will be attending the BIO event and hosting partnership meetings.

BIO International Conference : (http://www.bio.org)
Monday-Thursday June 19-22, 2017 ; San Diego Convention Center, San Diego, CA

About MimiVax: MimiVax is a privately held, clinical-stage immuno-oncology company focused on the development and commercialization of immunotherapeutics and targeted therapies for the treatment of cancer. Our proprietary product portfolio is based on technology licensed from Roswell Park Cancer Institute that targets survivin, a cell-survival protein that is present in most cancers and rarely detectable in normal tissue. Our therapies are designed to break immune tolerance and stimulate immune responses to control tumor growth and recurrence.

About SurVaxM: SurVaxM, our lead immunotherapeutic product, has demonstrated safety and tolerability in a Phase I study in people with malignant gliomas (brain tumors). SurVaxM is currently being evaluated in a Phase II clinical trial in adults with newly diagnosed glioblastoma at five cancer centers: Roswell Park Cancer Institute, Cleveland Clinic, Dana-Farber Cancer Institute, Mass General and Beth Israel Deaconess Hospitals. Also a Phase I clinical trial in combination with REVLIMID® (lenalidomide) as a maintenance therapy for adults with multiple myeloma (a form of blood cancer) is ongoing at Roswell Park.

Read the full story at http://www.prweb.com/releases/mimivax/survaxm/prweb14413751.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. PCI Appoints John Davis, PE, to Board
2. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
3. NeuroVive Appoints Anna Malm Bernsten and Boel Flodgren to its Board of Directors
4. SOTIO a.s. Appoints Chiltern International
5. Galien Foundation Appoints Kimberly Ha of Infinata’s BioPharm Insight to US Advisory Board
6. California Healthcare Institute Appoints Associate Director, Federal Government Relations and Programs
7. First Warning Systems, Inc., Appoints Veteran Medical Executive Royea as CEO
8. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
9. OHK Medical Devices appoints Mr. Omer Inbar as Chief Executive Officer
10. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
11. TNI BioTech, Inc. Appoints Industry Veteran, Dr. Joseph Fortunak, as a Strategic Consultant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its national ... Dr. Suneel I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based ... selected for membership in ARCS Alumni Hall of Fame . ASTER Labs ...
(Date:10/11/2017)...  VMS BioMarketing, a leading provider of patient support solutions, ... Educator (CNE) network, which will launch this week. The VMS ... care professionals to enhance the patient care experience by delivering ... health care professionals to help women who have been diagnosed ... ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and cooking ... initiative announced today. The bold new look is part of a transformation to ... into a significant growth period. , It will also expand its service offering from ...
(Date:10/10/2017)... 10, 2017 SomaGenics announced the receipt of ... develop RealSeq®-SC (Single Cell), expected to be the first ... (including microRNAs) from single cells using NGS methods. The ... to accelerate development of approaches to analyze the heterogeneity ... "New techniques for measuring levels of mRNAs in individual ...
Breaking Biology Technology:
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/27/2017)... , March 27, 2017  Catholic Health Services ... Management Systems Society (HIMSS) Analytics for achieving Stage ... Model sm . In addition, CHS previously earned ... hospitals using an electronic medical record (EMR). ... high level of EMR usage in an outpatient ...
Breaking Biology News(10 mins):